Trial Profile
RACHEL1: A Phase I Radiation and Checkpoint Blockade Trial in Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Mar 2022
Price :
$35
*
At a glance
- Drugs Bintrafusp alfa (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Adverse reactions
- Acronyms RACHEL1
- 03 Mar 2022 Status changed from active, no longer recruiting to completed.
- 14 Jul 2021 Planned End Date changed from 31 Dec 2020 to 31 Dec 2021.
- 14 Jul 2021 Planned primary completion date changed from 31 Dec 2020 to 31 Dec 2021.